Ingenuity Pathways Analysis to be deployed broadly to researchers at
Pfizer, integrated with internal solutions
REDWOOD CITY, Calif., April 15 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, and Pfizer Pharmaceuticals, Inc. (NYSE: PFE), the world's largest research-based biomedical and pharmaceutical company, announced a strategic partnership today. This new multi-year partnership promotes enterprise-wide deployment of IPA, enabling more researchers to use IPA for the exploration, interpretation, and analysis of life science information. In addition, Pfizer will integrate IPA and content from the Ingenuity knowledge base with other informatics solutions used throughout the Pfizer organization.
"We have selected Ingenuity as a partner to support our vision to implement an integrated and enterprise-scale pathway solution," stated Giles Day, Senior Director of the Targets and Mechanisms Informatics Group, Pfizer. "Through IPA, our internal scientists can access quality information to model and analyze complex biological and chemical systems and effectively share the information seamlessly across the organization. Our goal is to ensure our teams are selecting the best disease targets so that they will have higher confidence in the drug's mechanism of action and safety."
"In addition to IPA, we have been able to offer a suite of powerful
capabilities tailored specifically for Pfizer," stated Jake Leschly, CEO,
Ingenuity Systems. "By integrating IPA with internal platforms, scientists
are primed to unlock new insights from their data and internal information,
and are more equipped to make faster, data-based decisions about targets.
|SOURCE Ingenuity Systems|
Copyright©2008 PR Newswire.
All rights reserved